Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Prostate

Retrieve available abstracts of 261 articles:
HTML format
Text format



Single Articles


    April 2017
  1. CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
    Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
    PubMed     Text format     Abstract available


  2. JIA L, Gui B, Zheng D, Decker KF, et al
    Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
    PubMed     Text format     Abstract available


  3. TANG B, Han CT, Gan HL, Zhang GM, et al
    Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
    Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
    PubMed     Text format     Abstract available


  4. PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
    Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
    PubMed     Text format     Abstract available


  5. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
    When should active surveillance for prostate cancer stop if no progression is detected?
    Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
    PubMed     Text format     Abstract available


  6. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
    Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
    Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
    PubMed     Text format     Abstract available


  7. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
    External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
    Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
    PubMed     Text format     Abstract available


    March 2017
  8. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
    Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
    Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
    PubMed     Text format     Abstract available


  9. HABL G, Sauter K, Schiller K, Dewes S, et al
    68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
    PubMed     Text format     Abstract available


  10. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
    Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
    PubMed     Text format     Abstract available


  11. JOSEFSSON A, Linder A, Flondell Site D, Canesin G, et al
    Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naive Prostate Cancer.
    Prostate. 2017 Mar 10. doi: 10.1002/pros.23325.
    PubMed     Text format     Abstract available


  12. KHAN S, Cai J, Nielsen ME, Troester MA, et al
    The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.
    Prostate. 2017 Mar 6. doi: 10.1002/pros.23342.
    PubMed     Text format     Abstract available


  13. SZULKIN R, Clements MS, Magnusson PK, Wiklund FE, et al
    Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers.
    Prostate. 2017 Mar 1. doi: 10.1002/pros.23344.
    PubMed     Text format     Abstract available


    February 2017
  14. SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
    Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23326.
    PubMed     Text format     Abstract available


  15. ZHANG Q, Liu S, Ge D, Cunningham DM, et al
    Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23343.
    PubMed     Text format     Abstract available


  16. PILLING AB, Hwang O, Boudreault A, Laurent A, et al
    IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-alpha Signaling.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23327.
    PubMed     Text format     Abstract available


  17. ELSHAFAE SM, Kohart NA, Altstadt LA, Dirksen WP, et al
    The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
    Prostate. 2017 Feb 9. doi: 10.1002/pros.23318.
    PubMed     Text format     Abstract available


  18. VAN DIE MD, Williams SG, Emery J, Bone KM, et al
    A Placebo-Controlled Double-Blinded Randomized Pilot Study of Combination Phytotherapy in Biochemically Recurrent Prostate Cancer.
    Prostate. 2017 Feb 9. doi: 10.1002/pros.23317.
    PubMed     Text format     Abstract available


  19. LERTSUWAN K, Choe LH, Marwa IR, Lee K, et al
    Identification of Fibulin-1 as a Human Bone Marrow Stromal (HS-5) Sell-Derived Factor That Induces Human Prostate Cancer Cell Death.
    Prostate. 2017 Feb 7. doi: 10.1002/pros.23303.
    PubMed     Text format     Abstract available


  20. NGUYEN HM, Vessella RL, Morrissey C, Brown LG, et al
    LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
    Prostate. 2017 Feb 3. doi: 10.1002/pros.23313.
    PubMed     Text format     Abstract available


  21. ISHARWAL S, Modi S, Arora N, Uhlrich C 3rd, et al
    Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23298.
    PubMed     Text format     Abstract available


  22. DJUSBERG E, Jernberg E, Thysell E, Golovleva I, et al
    High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23307.
    PubMed     Text format     Abstract available


  23. DJALADAT H, Amini E, Xu W, Cai J, et al
    Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases.
    Prostate. 2017 Feb 1. doi: 10.1002/pros.23306.
    PubMed     Text format     Abstract available


    January 2017
  24. FITZGERALD LM, Naeem H, Makalic E, Schmidt DF, et al
    Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study.
    Prostate. 2017 Jan 24. doi: 10.1002/pros.23289.
    PubMed     Text format     Abstract available


  25. GRAFF RE, Judson G, Ahearn TU, Fiorentino M, et al
    Circulating antioxidant levels and risk of prostate cancer by TMPRSS2:ERG.
    Prostate. 2017 Jan 19. doi: 10.1002/pros.23312.
    PubMed     Text format     Abstract available


  26. KRATOCHVILOVA M, Raudenska M, Heger Z, Richtera L, et al
    Amino Acid Profiling of Zinc Resistant Prostate Cancer Cell Lines: Associations With Cancer Progression.
    Prostate. 2017 Jan 19. doi: 10.1002/pros.23304.
    PubMed     Text format     Abstract available


  27. CHOPRA A, Georgieva M, Lopes G, Yeo CM, et al
    Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Prostate. 2017 Jan 19. doi: 10.1002/pros.23309.
    PubMed     Text format     Abstract available


  28. WETTSTEIN MS, Saba K, Umbehr MH, Murtola TJ, et al
    Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.
    Prostate. 2017 Jan 17. doi: 10.1002/pros.23296.
    PubMed     Text format     Abstract available


  29. PARIKH RR, Byun J, Goyal S, Kim IY, et al
    Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer.
    Prostate. 2017 Jan 17. doi: 10.1002/pros.23294.
    PubMed     Text format     Abstract available


  30. LEYH-BANNURAH SR, Budaus L, Pompe R, Zaffuto E, et al
    North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer.
    Prostate. 2017 Jan 17. doi: 10.1002/pros.23292.
    PubMed     Text format     Abstract available


    December 2016
  31. ALVA A, Nordquist L, Daignault S, George S, et al
    Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
    Prostate. 2016 Dec 19. doi: 10.1002/pros.23286.
    PubMed     Text format     Abstract available


  32. CHEN M, Zhou B, Zhong P, Rajamanickam V, et al
    Increased Intracellular Reactive Oxygen Species Mediates the Anti-Cancer Effects of WZ35 via Activating Mitochondrial Apoptosis Pathway in Prostate Cancer Cells.
    Prostate. 2016 Dec 19. doi: 10.1002/pros.23287.
    PubMed     Text format     Abstract available


  33. FOJ L, Ferrer F, Serra M, Arevalo A, et al
    Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.
    Prostate. 2016 Dec 19. doi: 10.1002/pros.23295.
    PubMed     Text format     Abstract available


  34. SU S, Parris AB, Grossman G, Mohler JL, et al
    Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.
    Prostate. 2016 Dec 14. doi: 10.1002/pros.23288.
    PubMed     Text format     Abstract available


    November 2016
  35. EMAMI NC, Leong L, Wan E, Van Blarigan EL, et al
    Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.
    Prostate. 2016 Nov 30. doi: 10.1002/pros.23283.
    PubMed     Text format     Abstract available


  36. MASKO EM, Alfaqih MA, Solomon KR, Barry WT, et al
    Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
    Prostate. 2016 Nov 30. doi: 10.1002/pros.23282.
    PubMed     Text format     Abstract available


  37. HEMPEL HA, Cuka NS, Kulac I, Barber JR, et al
    Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence.
    Prostate. 2016 Nov 21. doi: 10.1002/pros.23280.
    PubMed     Text format     Abstract available


  38. WANG R, Zeidan AM, Yu JB, Soulos PR, et al
    Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
    Prostate. 2016 Nov 21. doi: 10.1002/pros.23281.
    PubMed     Text format     Abstract available


  39. MALDONADO-CARCELES AB, Sanchez-Rodriguez C, Vera-Porras EM, Arense-Gonzalo JJ, et al
    Anogenital Distance, a Biomarker of Prenatal Androgen Exposure Is Associated With Prostate Cancer Severity.
    Prostate. 2016 Nov 16. doi: 10.1002/pros.23279.
    PubMed     Text format     Abstract available


  40. ARMSTRONG AJ, Humeniuk MS, Healy P, Szmulewitz R, et al
    Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
    Prostate. 2016 Nov 16. doi: 10.1002/pros.23277.
    PubMed     Text format     Abstract available


  41. SULEK JE, Robinson SP, Petrossian AA, Zhou S, et al
    Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.
    Prostate. 2016 Nov 8. doi: 10.1002/pros.23275.
    PubMed     Text format     Abstract available


  42. MIYAZAWA Y, Sekine Y, Kato H, Furuya Y, et al
    Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
    Prostate. 2016 Nov 8. doi: 10.1002/pros.23273.
    PubMed     Text format     Abstract available


  43. GONZALEZ A, Garcia de Durango C, Alonso V, Bravo B, et al
    Distinct Osteomimetic Response of Androgen-Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Implications.
    Prostate. 2016 Nov 3. doi: 10.1002/pros.23270.
    PubMed     Text format     Abstract available


  44. LEE J, Lee MS, Jeoung DI, Kim YM, et al
    Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Prostate. 2016 Nov 3. doi: 10.1002/pros.23274.
    PubMed     Text format     Abstract available


  45. PANG J, Yang YW, Huang Y, Yang J, et al
    P110beta Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
    Prostate. 2016 Nov 1. doi: 10.1002/pros.23271.
    PubMed     Text format     Abstract available


  46. MIYAHIRA AK, Morris M, Soule HR
    Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
    Prostate. 2016 Nov 1. doi: 10.1002/pros.23272.
    PubMed     Text format     Abstract available


    October 2016
  47. CAPOGROSSO P, Ventimiglia E, Moschini M, Boeri L, et al
    Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine.
    Prostate. 2016 Oct 24. doi: 10.1002/pros.23266.
    PubMed     Text format     Abstract available


  48. JEFFERS A, Sochat V, Kattan MW, Yu C, et al
    Predicting Prostate Cancer Recurrence After Radical Prostatectomy.
    Prostate. 2016 Oct 24. doi: 10.1002/pros.23268.
    PubMed     Text format     Abstract available


  49. DEJIMA T, Imada K, Takeuchi A, Shiota M, et al
    Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.
    Prostate. 2016 Oct 24. doi: 10.1002/pros.23269.
    PubMed     Text format     Abstract available


  50. GEYBELS MS, McCloskey KD, Mills IG, Stanford JL, et al
    Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
    Prostate. 2016 Oct 18. doi: 10.1002/pros.23267.
    PubMed     Text format     Abstract available


  51. DELL'OGLIO P, Karnes RJ, Gandaglia G, Fossati N, et al
    The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.
    Prostate. 2016 Oct 18. doi: 10.1002/pros.23265.
    PubMed     Text format     Abstract available


  52. LEACH DA, Trotta AP, Need EF, Risbridger GP, et al
    The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.
    Prostate. 2016 Oct 8. doi: 10.1002/pros.23259.
    PubMed     Text format     Abstract available


  53. LIU J, Xiao M, Li J, Wang D, et al
    Activation of UPR Signaling Pathway is Associated With the Malignant Progression and Poor Prognosis in Prostate Cancer.
    Prostate. 2016 Oct 8. doi: 10.1002/pros.23264.
    PubMed     Text format     Abstract available


  54. DI SEBASTIANO KM, Pinthus JH, Duivenvoorden WC, Patterson L, et al
    Elevated C-Peptides, Abdominal Obesity, and Abnormal Adipokine Profile are Associated With Higher Gleason Scores in Prostate Cancer.
    Prostate. 2016 Oct 4. doi: 10.1002/pros.23262.
    PubMed     Text format     Abstract available


  55. SHOAIBI A, Rao GA, Cai B, Rawl J, et al
    Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
    Prostate. 2016 Oct 4. doi: 10.1002/pros.23258.
    PubMed     Text format     Abstract available


  56. IMADA K, Shiota M, Kuroiwa K, Sugimoto M, et al
    FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
    Prostate. 2016 Oct 4. doi: 10.1002/pros.23254.
    PubMed     Text format     Abstract available


  57. OTSUKI H, Kimura T, Yamaga T, Kosaka T, et al
    Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
    Prostate. 2016 Oct 3. doi: 10.1002/pros.23263.
    PubMed     Text format     Abstract available


  58. TALESA VN, Ferri I, Bellezza G, Love HD, et al
    Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
    Prostate. 2016 Oct 3. doi: 10.1002/pros.23261.
    PubMed     Text format     Abstract available


    September 2016
  59. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
    Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.
    Prostate. 2016 Sep 29. doi: 10.1002/pros.23255.
    PubMed     Text format     Abstract available


  60. LEYH-BANNURAH SR, Gazdovich S, Budaus L, Zaffuto E, et al
    Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients.
    Prostate. 2016 Sep 29. doi: 10.1002/pros.23253.
    PubMed     Text format     Abstract available


  61. MIYAHIRA AK, Roychowdhury S, Goswami S, Ippolito JE, et al
    Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2016 Sep 28. doi: 10.1002/pros.23260.
    PubMed     Text format     Abstract available


  62. BARRETT CS, Millena AC, Khan SA
    TGF-beta Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
    Prostate. 2016 Sep 7. doi: 10.1002/pros.23250.
    PubMed     Text format     Abstract available


    August 2016
  63. WULANINGSIH W, Astuti Y, Matsuguchi T, Anggrandariyanny P, et al
    Circulating Prostate-Specific Antigen and Telomere Length in a Nationally Representative Sample of Men Without History of Prostate Cancer.
    Prostate. 2016 Aug 27. doi: 10.1002/pros.23245.
    PubMed     Text format     Abstract available


  64. LEE CH, Ku JY, Ha JM, Bae SS, et al
    Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Prostate. 2016 Aug 22. doi: 10.1002/pros.23248.
    PubMed     Text format     Abstract available


  65. CHAKRAVARTHI BV, Goswami MT, Pathi SS, Dodson M, et al
    Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.
    Prostate. 2016 Aug 22. doi: 10.1002/pros.23243.
    PubMed     Text format     Abstract available


  66. ALBRIGHT FS, Stephenson RA, Agarwal N, Cannon-Albright LA, et al
    Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23247.
    PubMed     Text format     Abstract available


  67. MAUGHAN BL, Luber B, Nadal R, Antonarakis ES, et al
    Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23246.
    PubMed     Text format     Abstract available


  68. ASAI A, Miyata Y, Matsuo T, Shida Y, et al
    Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23244.
    PubMed     Text format     Abstract available


  69. CASTIGLIONE F, Dell'Oglio P, Tosco L, Everaerts W, et al
    Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23242.
    PubMed     Text format     Abstract available


  70. FU W, Tao T, Qi M, Wang L, et al
    MicroRNA-132/212 Upregulation Inhibits TGF-beta-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
    Prostate. 2016 Aug 16. doi: 10.1002/pros.23241.
    PubMed     Text format     Abstract available


    July 2016
  71. NAKATA D, Nakayama K, Masaki T, Tanaka A, et al
    Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Prostate. 2016 Jul 30. doi: 10.1002/pros.23238.
    PubMed     Text format     Abstract available


  72. BRUCE HM, Stricker PD, Gupta R, Savdie RR, et al
    Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.
    Prostate. 2016 Jul 30. doi: 10.1002/pros.23233.
    PubMed     Text format     Abstract available


  73. CATHOMAS R, Crabb SJ, Mark M, Winterhalder R, et al
    Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
    Prostate. 2016 Jul 25. doi: 10.1002/pros.23236.
    PubMed     Text format     Abstract available


  74. DAI L, Li J, Xing M, Sanchez TW, et al
    Using serological proteome analysis to identify serum anti-nucleophosmin 1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer.
    Prostate. 2016 Jul 15. doi: 10.1002/pros.23217.
    PubMed     Text format     Abstract available


  75. KOCEMBA KA, Dudzik P, Ostrowska B, Laidler P, et al
    Incorrect analysis of MCAM gene promoter methylation in prostate cancer.
    Prostate. 2016 Jul 15. doi: 10.1002/pros.23210.
    PubMed     Text format    


  76. WU JC, Wang CT, Hung HC, Wu WJ, et al
    Heteronemin is a novel c-Met/STAT3 inhibitor against advanced prostate cancer cells.
    Prostate. 2016 Jul 15. doi: 10.1002/pros.23230.
    PubMed     Text format     Abstract available


  77. WHITE-AL HABEEB NM, Garcia J, Fleshner N, Bapat B, et al
    Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23235.
    PubMed     Text format     Abstract available


  78. MARKOWSKI MC, Frick KD, Eshleman JR, Luo J, et al
    Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23232.
    PubMed     Text format     Abstract available


  79. AL-BAKHEIT A, Traka M, Saha S, Mithen R, et al
    Accumulation of palmitoylcarnitine and its effect on pro-inflammatory pathways and calcium influx in prostate cancer.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23222.
    PubMed     Text format     Abstract available


  80. FARACH A, Ding Y, Lee M, Creighton C, et al
    Neuronal trans-differentiation in prostate cancer cells.
    Prostate. 2016 Jul 12. doi: 10.1002/pros.23221.
    PubMed     Text format     Abstract available


  81. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
    Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
    Prostate. 2016;76:917-26.
    PubMed     Text format     Abstract available


  82. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
    Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Prostate. 2016;76:905-16.
    PubMed     Text format     Abstract available


    June 2016
  83. DOGAN A, Demirci S, Turkmen NB, Caglayan AB, et al
    Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice.
    Prostate. 2016 Jun 24. doi: 10.1002/pros.23229.
    PubMed     Text format     Abstract available


  84. LIANG P, Henning SM, Schokrpur S, Wu L, et al
    Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression.
    Prostate. 2016 Jun 24. doi: 10.1002/pros.23218.
    PubMed     Text format     Abstract available


  85. SCHWEIZER MT, Wang H, Luber B, Nadal R, et al
    Bipolar androgen therapy for men with androgen ablation naive prostate cancer: Results from the phase II BATMAN study.
    Prostate. 2016 Jun 24. doi: 10.1002/pros.23209.
    PubMed     Text format     Abstract available


  86. CUNNINGHAM D, Parajuli KR, Zhang C, Wang G, et al
    Monomethyl auristatin e phosphate inhibits human prostate cancer growth.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23226.
    PubMed     Text format     Abstract available


  87. KULAC I, Gumuskaya B, Drake CG, Gonzalez B, et al
    Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial .
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23224.
    PubMed     Text format     Abstract available


  88. XIE W, Drouin S, Nakabayashi M, Pomerantz M, et al
    A genetic variation of SOD2 does not determine duration of response to androgen deprivation therapy for prostate cancer.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23220.
    PubMed     Text format     Abstract available


  89. CHENG HH, Klemfuss N, Montgomery B, Higano CS, et al
    A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23219.
    PubMed     Text format     Abstract available


  90. JUNGHANS RP, Ma Q, Rathore R, Gomes EM, et al
    Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response.
    Prostate. 2016 Jun 21. doi: 10.1002/pros.23214.
    PubMed     Text format     Abstract available


  91. MURPHY C, True L, Vakar-Lopez F, Xia J, et al
    A novel system for estimating residual disease and pathologic response to neoadjuvant treatment of prostate cancer.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23215.
    PubMed     Text format     Abstract available


  92. XIAO L, Lanz RB, Frolov A, Castro PD, et al
    The germ cell gene TDRD1 as an ERG target gene and a novel prostate cancer biomarker.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23213.
    PubMed     Text format     Abstract available


  93. SHAHABI A, Lewinger JP, Ren J, April C, et al
    Novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early stage prostate cancer patients.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23211.
    PubMed     Text format     Abstract available


  94. MIYAHIRA AK, Simons JW, Soule HR
    The 22nd annual prostate cancer foundation scientific retreat report.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23193.
    PubMed     Text format     Abstract available


  95. SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
    Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23192.
    PubMed     Text format     Abstract available


  96. SHOURIDEH M, DePriest A, Mohler JL, Wilson EM, et al
    Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23190.
    PubMed     Text format     Abstract available


  97. ANTWI SO, Steck SE, Su LJ, Hebert JR, et al
    Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP).
    Prostate. 2016 Jun 8. doi: 10.1002/pros.23189.
    PubMed     Text format     Abstract available


  98. UDAGER AM, DeMarzo AM, Shi Y, Hicks JL, et al
    Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
    Prostate. 2016;76:845-53.
    PubMed     Text format     Abstract available


  99. PAN X, Zhang X, Gong J, Tan J, et al
    The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
    Prostate. 2016;76:823-33.
    PubMed     Text format     Abstract available


  100. MCILWAIN DW, Zoetemelk M, Myers JD, Edwards MT, et al
    Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate.
    Prostate. 2016;76:722-34.
    PubMed     Text format     Abstract available


  101. HENNING JD, Bunker CH, Patrick AL, Jenkins FJ, et al
    Human herpesvirus 8 establishes a latent infection in prostates of Tobago men resulting in increased macrophage infiltration.
    Prostate. 2016;76:735-43.
    PubMed     Text format     Abstract available


  102. AKINBOYE ES, Brennen WN, Rosen DM, Bakare O, et al
    Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Prostate. 2016;76:703-14.
    PubMed     Text format     Abstract available


    May 2016
  103. ELLIS L, Ku S, Li Q, Azabdaftari G, et al
    Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer.
    Prostate. 2016 May 26. doi: 10.1002/pros.23206.
    PubMed     Text format     Abstract available


  104. GLEICHER S, Kauffman EC, Kotula L, Bratslavsky G, et al
    Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers.
    Prostate. 2016 May 26. doi: 10.1002/pros.23204.
    PubMed     Text format     Abstract available


  105. KRYVENKO ON, Epstein JI
    Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3 + 3 = 6 prostate cancer.
    Prostate. 2016 May 26. doi: 10.1002/pros.23199.
    PubMed     Text format    


  106. CUI T, Hester AG, Seeds MC, Rahbar E, et al
    Impact of genetic and epigenetic variations within the FADS cluster on the composition and metabolism of polyunsaturated fatty acids in prostate cancer.
    Prostate. 2016 May 16. doi: 10.1002/pros.23205.
    PubMed     Text format     Abstract available


  107. MUTHUSWAMY R, Corman JM, Dahl K, Chatta GS, et al
    Functional reprogramming of human prostate cancer to promote local attraction of effector CD8 T cells.
    Prostate. 2016 May 16. doi: 10.1002/pros.23194.
    PubMed     Text format     Abstract available


  108. HECK MM, Thalgott M, Schmid SC, Oh WK, et al
    A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer.
    Prostate. 2016 May 16. doi: 10.1002/pros.23202.
    PubMed     Text format     Abstract available


  109. LYNCH SM, O'Neill KM, McKenna MM, Walsh CP, et al
    Regulation of miR-200c and miR-141 by methylation in prostate cancer.
    Prostate. 2016 May 16. doi: 10.1002/pros.23201.
    PubMed     Text format     Abstract available


  110. CHEN H, Liu X, Brendler CB, Ankerst DP, et al
    Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Prostate. 2016 May 16. doi: 10.1002/pros.23200.
    PubMed     Text format     Abstract available


  111. KUMAR D, Gupta A, Mandhani A, Sankhwar SN, et al
    NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
    Prostate. 2016 May 16. doi: 10.1002/pros.23198.
    PubMed     Text format     Abstract available


  112. GREENE DJ, Elshafei A, Nyame YA, Kara O, et al
    External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
    Prostate. 2016 May 16. doi: 10.1002/pros.23197.
    PubMed     Text format     Abstract available


  113. LARBI A, Dallaudiere B, Pasoglou V, Padhani A, et al
    Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
    Prostate. 2016 May 16. doi: 10.1002/pros.23196.
    PubMed     Text format     Abstract available


  114. SAKAI M, Martinez-Arguelles DB, Aprikian AG, Magliocco AM, et al
    De novo steroid biosynthesis in human prostate cell lines and biopsies.
    Prostate. 2016;76:575-87.
    PubMed     Text format     Abstract available


  115. PADMANABHAN A, Rao V, De Marzo AM, Bieberich CJ, et al
    Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants.
    Prostate. 2016;76:523-33.
    PubMed     Text format     Abstract available


  116. BRENNEN WN, Kisteman LN, Isaacs JT
    Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.
    Prostate. 2016;76:552-64.
    PubMed     Text format     Abstract available


  117. HEGER Z, Gumulec J, Cernei N, Polanska H, et al
    Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines.
    Prostate. 2016;76:679-90.
    PubMed     Text format     Abstract available


    April 2016
  118. VAN NESTE L, Partin AW, Stewart GD, Epstein JI, et al
    Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Prostate. 2016 Apr 28. doi: 10.1002/pros.23191.
    PubMed     Text format     Abstract available


  119. YOSHIKAWA T, Kobori G, Goto T, Akamatsu S, et al
    An original patient-derived xenograft of prostate cancer with cyst formation.
    Prostate. 2016 Apr 21. doi: 10.1002/pros.23188.
    PubMed     Text format     Abstract available


  120. SZARVAS T, Reis H, Vom Dorp F, Tschirdewahn S, et al
    Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
    Prostate. 2016 Apr 7. doi: 10.1002/pros.23186.
    PubMed     Text format     Abstract available


  121. GUAN Y, Wu Y, Liu Y, Ni J, et al
    Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Prostate. 2016 Apr 4. doi: 10.1002/pros.23187.
    PubMed     Text format     Abstract available


  122. TUMMALA R, Nadiminty N, Lou W, Evans CP, et al
    Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.
    Prostate. 2016;76:445-55.
    PubMed     Text format     Abstract available


  123. KESKIVALI T, Kujala P, Visakorpi T, Tammela TL, et al
    Statin use and risk of disease recurrence and death after radical prostatectomy.
    Prostate. 2016;76:469-78.
    PubMed     Text format     Abstract available


    March 2016
  124. CHA YJ, Lee JH, Han HH, Kim BG, et al
    MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
    Prostate. 2016 Mar 28. doi: 10.1002/pros.23183.
    PubMed     Text format     Abstract available


  125. DE MORREE E, van Soest R, Aghai A, de Ridder C, et al
    Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    Prostate. 2016 Mar 21. doi: 10.1002/pros.23182.
    PubMed     Text format     Abstract available


  126. ROUDIER MP, Winters BR, Coleman I, Lam HM, et al
    Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Prostate. 2016 Mar 16. doi: 10.1002/pros.23171.
    PubMed     Text format     Abstract available


  127. NAM RK, Benatar T, Wallis CJ, Amemiya Y, et al
    MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Prostate. 2016 Mar 15. doi: 10.1002/pros.23177.
    PubMed     Text format     Abstract available


  128. CREMERS RG, Aben KK, van Oort IM, Sedelaar JP, et al
    The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.
    Prostate. 2016 Mar 14. doi: 10.1002/pros.23179.
    PubMed     Text format     Abstract available


  129. HERNANDEZ S, Font-Tello A, Juanpere N, de Muga S, et al
    Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Prostate. 2016 Mar 9. doi: 10.1002/pros.23176.
    PubMed     Text format     Abstract available


  130. DING H, Kothandaraman S, Gong L, Williams MM, et al
    A human GRPr-transfected Ace-1 canine prostate cancer model in mice.
    Prostate. 2016 Mar 4. doi: 10.1002/pros.23172.
    PubMed     Text format     Abstract available


  131. ELSHAFAE SM, Hassan BB, Supsavhad W, Dirksen WP, et al
    Gastrin-releasing peptide receptor (GRPr) promotes EMT, growth, and invasion in canine prostate cancer.
    Prostate. 2016 Mar 4. doi: 10.1002/pros.23154.
    PubMed     Text format     Abstract available


  132. TORABI-NEZHAD S, Malekmakan L, Mashayekhi M, Daneshian A, et al
    Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63.
    Prostate. 2016;76:394-401.
    PubMed     Text format     Abstract available


    February 2016
  133. HIJAZI S, Meller B, Leitsmann C, Strauss A, et al
    See the unseen: Mesorectal lymph node metastases in prostate cancer.
    Prostate. 2016 Feb 16. doi: 10.1002/pros.23168.
    PubMed     Text format     Abstract available


  134. FORBES A, Anoopkumar-Dukie S, Chess-Williams R, McDermott C, et al
    Relative cytotoxic potencies and cell death mechanisms of alpha -adrenoceptor antagonists in prostate cancer cell lines.
    Prostate. 2016 Feb 16. doi: 10.1002/pros.23167.
    PubMed     Text format     Abstract available


  135. DOSHI C, Vacchio M, Attwood K, Murekeyisoni C, et al
    Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer.
    Prostate. 2016 Feb 16. doi: 10.1002/pros.23166.
    PubMed     Text format     Abstract available


  136. HORIGUCHI A, Tsujita K, Irisawa K, Kasamatsu T, et al
    A pilot study of photoacoustic imaging system for improved real-time visualization of neurovascular bundle during radical prostatectomy.
    Prostate. 2016;76:307-15.
    PubMed     Text format     Abstract available


  137. NOSOV A, Reva S, Petrov S, Mamijev E, et al
    Neoadjuvant chemotherapy using reduced-dose docetaxel followed by radical prostatectomy for patients with intermediate and high-risk prostate cancer: a single-center study.
    Prostate. 2016 Feb 11. doi: 10.1002/pros.23165.
    PubMed     Text format     Abstract available


  138. KAWAHARA T, Aljarah AK, Shareef HK, Inoue S, et al
    Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
    Prostate. 2016 Feb 11. doi: 10.1002/pros.23164.
    PubMed     Text format     Abstract available


  139. CHA HR, Lee JH, Hensel JA, Sawant AB, et al
    Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages.
    Prostate. 2016 Feb 9. doi: 10.1002/pros.23155.
    PubMed     Text format     Abstract available


  140. XIE W, Yang M, Chan J, Sun T, et al
    Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
    Prostate. 2016 Feb 5. doi: 10.1002/pros.23160.
    PubMed     Text format     Abstract available


  141. LIU X, Han W, Gulla S, Simon NI, et al
    Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
    Prostate. 2016 Feb 5. doi: 10.1002/pros.23157.
    PubMed     Text format     Abstract available


  142. LYNCH SM, McKenna MM, Walsh CP, McKenna DJ, et al
    miR-24 regulates CDKN1B/p27 expression in prostate cancer.
    Prostate. 2016 Feb 5. doi: 10.1002/pros.23156.
    PubMed     Text format     Abstract available


  143. MELLING N, Taskin B, Hube-Magg C, Kluth M, et al
    Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
    Prostate. 2016;76:259-72.
    PubMed     Text format     Abstract available


  144. NICKKHOLGH B, Fang X, Winters SM, Raina A, et al
    Cell line modeling to study biomarker panel in prostate cancer.
    Prostate. 2016;76:245-58.
    PubMed     Text format     Abstract available


  145. NIRAULA S, Templeton AJ, Vera-Badillo FE, Joshua AM, et al
    Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Prostate. 2016;76:235-42.
    PubMed     Text format     Abstract available


  146. ARAUJO CL, Quintero IB, Ovaska K, Herrala AM, et al
    Transmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle.
    Prostate. 2016;76:151-62.
    PubMed     Text format     Abstract available


    January 2016
  147. SHUI IM, Kolb S, Hanson C, Sutcliffe S, et al
    Trichomonas vaginalis infection and risk of advanced prostate cancer.
    Prostate. 2016 Jan 28. doi: 10.1002/pros.23153.
    PubMed     Text format     Abstract available


  148. NAKKEN HL, Lephart ED, Hopkins TJ, Shaw B, et al
    Prenatal exposure to soy and selenium reduces prostate cancer risk factors in TRAMP mice more than exposure beginning at six weeks.
    Prostate. 2016 Jan 28. doi: 10.1002/pros.23150.
    PubMed     Text format     Abstract available


  149. VON HARDENBERG J, Schwartz M, Werner T, Fuxius S, et al
    Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23152.
    PubMed     Text format     Abstract available


  150. HU BR, Fairey AS, Madhav A, Yang D, et al
    AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23151.
    PubMed     Text format     Abstract available


  151. WINCHESTER DA, Gurel B, Till C, Goodman PJ, et al
    Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23147.
    PubMed     Text format     Abstract available


  152. FU X, Zhang W, Su Y, Lu L, et al
    MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.
    Prostate. 2016 Jan 15. doi: 10.1002/pros.23143.
    PubMed     Text format     Abstract available


  153. PAXIMADIS P, Najy AJ, Snyder M, Kim HC, et al
    The interaction between androgen receptor and PDGF-D in the radiation response of prostate carcinoma.
    Prostate. 2016 Jan 6. doi: 10.1002/pros.23135.
    PubMed     Text format     Abstract available


  154. HOFNER T, Klein C, Eisen C, Rigo-Watermeier T, et al
    The influence of prostatic anatomy and neurotrophins on basal prostate epithelial progenitor cells.
    Prostate. 2016;76:114-21.
    PubMed     Text format     Abstract available


  155. PEDROSA AR, Graca JL, Carvalho S, Peleteiro MC, et al
    Notch signaling dynamics in the adult healthy prostate and in prostatic tumor development.
    Prostate. 2016;76:80-96.
    PubMed     Text format     Abstract available


  156. CORBIN JM, Overcash RF, Wren JD, Coburn A, et al
    Analysis of TMEFF2 allografts and transgenic mouse models reveals roles in prostate regeneration and cancer.
    Prostate. 2016;76:97-113.
    PubMed     Text format     Abstract available


    December 2015
  157. HERRMANN VL, Wieland DE, Legler DF, Wittmann V, et al
    The STEAP1 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-a new approach to immunotherapy against prostate carcinoma.
    Prostate. 2015 Dec 30. doi: 10.1002/pros.23136.
    PubMed     Text format     Abstract available


  158. KRYVENKO ON, Epstein JI
    Changes in prostate cancer grading: Including a new patient-centric grading system.
    Prostate. 2015 Dec 28. doi: 10.1002/pros.23142.
    PubMed     Text format     Abstract available


  159. KIBEL AS, Ahn J, Isikbay M, Klim A, et al
    Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
    Prostate. 2015 Dec 28. doi: 10.1002/pros.23139.
    PubMed     Text format     Abstract available


  160. KARATAS OF, Guzel E, Duz MB, Ittmann M, et al
    The role of ATP-binding cassette transporter genes in the progression of prostate cancer.
    Prostate. 2015 Dec 28. doi: 10.1002/pros.23137.
    PubMed     Text format     Abstract available


  161. NADAL R, Tsai HL, Sinibaldi VJ, Paller CJ, et al
    Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
    Prostate. 2015 Dec 22. doi: 10.1002/pros.23141.
    PubMed     Text format     Abstract available


  162. MAGNUSSON LU, Hagberg MT, Plas P, Olsson A, et al
    Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Prostate. 2015 Dec 10. doi: 10.1002/pros.23133.
    PubMed     Text format     Abstract available


  163. MCCROW JP, Petersen DC, Louw M, Chan EK, et al
    Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men.
    Prostate. 2015 Dec 10. doi: 10.1002/pros.23126.
    PubMed     Text format     Abstract available


  164. RAUSCHENBERGER L, Staar D, Thom K, Scharf C, et al
    Exosomal particles secreted by prostate cancer cells are potent mRNA and protein vehicles for the interference of tumor and tumor environment.
    Prostate. 2015 Dec 8. doi: 10.1002/pros.23132.
    PubMed     Text format     Abstract available


  165. SEEDHOUSE SJ, Affronti HC, Karasik E, Gillard BM, et al
    Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
    Prostate. 2015 Dec 8. doi: 10.1002/pros.23127.
    PubMed     Text format     Abstract available


  166. GERKE TA, Martin NE, Ding Z, Nuttall EJ, et al
    Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
    Prostate. 2015;75:1926-1933.
    PubMed     Text format     Abstract available


  167. PAYNE ONDRACEK R, Cheng J, Gangavarapu KJ, Azabdaftari G, et al
    Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.
    Prostate. 2015;75:1910-5.
    PubMed     Text format     Abstract available


  168. ZAPATA D, Howard LE, Allott EH, Hamilton RJ, et al
    Is PSA related to serum cholesterol and does the relationship differ between black and white men?
    Prostate. 2015;75:1877-85.
    PubMed     Text format     Abstract available


    November 2015
  169. MIYOSHI Y, Uemura H, Umemoto S, Sakamaki K, et al
    Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naive prostate cancer.
    Prostate. 2015 Nov 30. doi: 10.1002/pros.23129.
    PubMed     Text format     Abstract available


  170. BONKHOFF H
    Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
    Prostate. 2015 Nov 30. doi: 10.1002/pros.23128.
    PubMed     Text format     Abstract available


  171. NORDSTROM T, Van Blarigan EL, Ngo V, Roy R, et al
    Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
    Prostate. 2015 Nov 20. doi: 10.1002/pros.23125.
    PubMed     Text format     Abstract available


  172. DIPIPPO VA, Nguyen HM, Brown LG, Olson WC, et al
    Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
    Prostate. 2015 Nov 20. doi: 10.1002/pros.23124.
    PubMed     Text format     Abstract available


  173. LAITINEN VH, Akinrinade O, Rantapero T, Tammela TL, et al
    Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
    Prostate. 2015 Nov 10. doi: 10.1002/pros.23123.
    PubMed     Text format     Abstract available


  174. KARACOSTA LG, Kuroski LA, Hofmann WA, Azabdaftari G, et al
    Nucleoporin 62 and Ca /calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Prostate. 2015 Nov 10. doi: 10.1002/pros.23121.
    PubMed     Text format     Abstract available


  175. MILES FL, Kurtoglu S, Ahmer C, Soori M, et al
    Transforming growth factor-beta signaling induced during prostate cancer cell death and neuroendocrine differentiation is mediated by bone marrow stromal cells.
    Prostate. 2015;75:1802-13.
    PubMed     Text format     Abstract available


  176. HORNING AM, Awe JA, Wang CM, Liu J, et al
    DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Prostate. 2015;75:1790-801.
    PubMed     Text format     Abstract available


  177. NORDBY Y, Andersen S, Richardsen E, Ness N, et al
    Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
    Prostate. 2015;75:1682-93.
    PubMed     Text format     Abstract available


  178. WINTERS B, Plymate S, Zeliadt SB, Holt S, et al
    Metformin effects on biochemical recurrence and metabolic signaling in the prostate.
    Prostate. 2015;75:1694-703.
    PubMed     Text format     Abstract available


    October 2015
  179. KANG M, Lee KH, Lee HS, Park YH, et al
    PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
    Prostate. 2015 Oct 26. doi: 10.1002/pros.23118.
    PubMed     Text format     Abstract available


  180. CASTANARES MA, Copeland BT, Chowdhury WH, Liu MM, et al
    Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.
    Prostate. 2015 Oct 26. doi: 10.1002/pros.23115.
    PubMed     Text format     Abstract available


  181. SANCHEZ-SALAS R, Olivier F, Prapotnich D, Dancausa J, et al
    First off-time treatment prostate-specific antigen kinetics predicts survival in intermittent androgen deprivation for prostate cancer.
    Prostate. 2015 Oct 26. doi: 10.1002/pros.23098.
    PubMed     Text format     Abstract available


  182. POSADAS EM, Ahmed RS, Karrison T, Szmulewitz RZ, et al
    Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
    Prostate. 2015 Oct 23. doi: 10.1002/pros.23119.
    PubMed     Text format     Abstract available


  183. PAGANO MJ, Whalen MJ, Paulucci DJ, Reddy BN, et al
    Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
    Prostate. 2015 Oct 20. doi: 10.1002/pros.23114.
    PubMed     Text format     Abstract available


  184. SAETER T, Bogaard M, Vlatkovic L, Waaler G, et al
    The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort.
    Prostate. 2015 Oct 19. doi: 10.1002/pros.23112.
    PubMed     Text format     Abstract available


  185. ZHAO Z, He J, Kang R, Zhao S, et al
    RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
    Prostate. 2015 Oct 19. doi: 10.1002/pros.23110.
    PubMed     Text format     Abstract available


  186. MIYAHIRA AK, Lang JM, Den RB, Garraway IP, et al
    Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2015 Oct 19. doi: 10.1002/pros.23107.
    PubMed     Text format     Abstract available


  187. MIAN OY, Khattab MH, Hedayati M, Coulter J, et al
    GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress.
    Prostate. 2015 Oct 8. doi: 10.1002/pros.23111.
    PubMed     Text format     Abstract available


  188. SUN A, Li C, Chen R, Huang Y, et al
    GSK-3beta controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells.
    Prostate. 2015 Oct 6. doi: 10.1002/pros.23106.
    PubMed     Text format     Abstract available


  189. WANG H, Zhang L, Fu Y, Fang F, et al
    CSL regulates AKT to mediate androgen independence in prostate cancer progression.
    Prostate. 2015 Oct 6. doi: 10.1002/pros.23104.
    PubMed     Text format     Abstract available


    September 2015
  190. ELISHMERENI M, Kheifetz Y, Shukrun I, Bevan GH, et al
    Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
    Prostate. 2015 Sep 30. doi: 10.1002/pros.23099.
    PubMed     Text format     Abstract available


  191. SAMSONOV R, Shtam T, Burdakov V, Glotov A, et al
    Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic.
    Prostate. 2015 Sep 29. doi: 10.1002/pros.23101.
    PubMed     Text format     Abstract available


  192. BADRISING SK, van der Noort V, van den Eertwegh AJ, Hamberg P, et al
    Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
    Prostate. 2015 Sep 22. doi: 10.1002/pros.23094.
    PubMed     Text format     Abstract available


  193. HERNANDEZ-ARGUELLO M, Quiceno H, Pascual I, Solorzano JL, et al
    Index lesion characterization by C-Choline PET/CT and Apparent Diffusion Coefficient parameters at 3 Tesla MRI in primary prostate carcinoma.
    Prostate. 2015 Sep 22. doi: 10.1002/pros.23038.
    PubMed     Text format     Abstract available


  194. ELSHAFEI A, Chevli KK, Moussa AS, Kara O, et al
    PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Prostate. 2015 Sep 18. doi: 10.1002/pros.23096.
    PubMed     Text format     Abstract available


  195. GOERING W, Schmitt K, Dostert M, Schaal H, et al
    Human endogenous retrovirus HERV-K(HML-2) activity in prostate cancer is dominated by a few loci.
    Prostate. 2015 Sep 18. doi: 10.1002/pros.23095.
    PubMed     Text format     Abstract available


  196. GEYBELS MS, Zhao S, Wong CJ, Bibikova M, et al
    Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Prostate. 2015 Sep 18. doi: 10.1002/pros.23093.
    PubMed     Text format     Abstract available


  197. KAMPJARVI K, Kim NH, Keskitalo S, Clark AD, et al
    Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
    Prostate. 2015 Sep 18. doi: 10.1002/pros.23092.
    PubMed     Text format     Abstract available


  198. SUN Q, Arnold RS, Q Sun C, A Petros J, et al
    A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer.
    Prostate. 2015 Sep 18. doi: 10.1002/pros.23089.
    PubMed     Text format     Abstract available


  199. HIJAZI S, Meller B, Leitsmann C, Strauss A, et al
    Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by Ga-PSMA-positron emission tomography/computerized tomography.
    Prostate. 2015 Sep 10. doi: 10.1002/pros.23091.
    PubMed     Text format     Abstract available


  200. LIU Y, Zhao X, Sun X, Li Y, et al
    Expression of IL-17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia.
    Prostate. 2015 Sep 10. doi: 10.1002/pros.23058.
    PubMed     Text format     Abstract available


  201. GOTO T, Terada N, Inoue T, Kobayashi T, et al
    Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer.
    Prostate. 2015 Sep 1. doi: 10.1002/pros.23088.
    PubMed     Text format     Abstract available


  202. ADISSU HA, McKerlie C, Grappa MD, Waterhouse P, et al
    Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
    Prostate. 2015 Sep 1. doi: 10.1002/pros.23056.
    PubMed     Text format     Abstract available


  203. VENIER NA, Yamamoto T, Sugar LM, Adomat H, et al
    Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.
    Prostate. 2015;75:1300-11.
    PubMed     Text format     Abstract available


  204. SIADAT F, Sykes J, Zlotta AR, Aldaoud N, et al
    Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.
    Prostate. 2015;75:1277-84.
    PubMed     Text format     Abstract available


  205. ELSHAFEI A, Kovac E, Dhar N, Levy D, et al
    A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.
    Prostate. 2015;75:1447-53.
    PubMed     Text format     Abstract available


  206. MANDEL P, Weinhold P, Michl U, Huland H, et al
    Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy.
    Prostate. 2015;75:1436-46.
    PubMed     Text format     Abstract available


    August 2015
  207. HAMID AR, Hoogland AM, Smit F, Jannink S, et al
    The role of HOXC6 in prostate cancer development.
    Prostate. 2015 Aug 27. doi: 10.1002/pros.23065.
    PubMed     Text format     Abstract available


  208. HEIDEGGER I, Hofer J, Luger M, Pichler R, et al
    Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
    Prostate. 2015 Aug 26. doi: 10.1002/pros.23086.
    PubMed     Text format     Abstract available


  209. XU B, Huang Y, Niu X, Tao T, et al
    Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1.
    Prostate. 2015 Aug 26. doi: 10.1002/pros.23068.
    PubMed     Text format     Abstract available


  210. QUEK SI, Wong OM, Chen A, Borges GT, et al
    Processing of voided urine for prostate cancer RNA biomarker analysis.
    Prostate. 2015 Aug 26. doi: 10.1002/pros.23066.
    PubMed     Text format     Abstract available


  211. MAUGHAN BL, Xhou XC, Suzman DL, Nadal R, et al
    Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Prostate. 2015 Aug 26. doi: 10.1002/pros.23064.
    PubMed     Text format     Abstract available


  212. CIFTCI S, Yilmaz H, Ciftci E, Simsek E, et al
    Perineural invasion in prostate biopsy specimens is associated with increased bone metastasis in prostate cancer.
    Prostate. 2015 Aug 19. doi: 10.1002/pros.23067.
    PubMed     Text format     Abstract available


  213. TING F, van Leeuwen PJ, Delprado W, Haynes AM, et al
    Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.
    Prostate. 2015 Aug 18. doi: 10.1002/pros.23062.
    PubMed     Text format     Abstract available


  214. LEISSER A, Pruscha K, Ubl P, Wadsak W, et al
    Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [ C]acetate PET as a prognostic marker.
    Prostate. 2015 Aug 18. doi: 10.1002/pros.23061.
    PubMed     Text format     Abstract available


  215. DWIVEDI S, Goel A, Mandhani A, Khattri S, et al
    Functional genetic variability at promoters of pro-(IL-18) and anti-(IL-10) inflammatory affects their mRNA expression and survival in prostate carcinoma patients: Five year follow-up study.
    Prostate. 2015 Aug 17. doi: 10.1002/pros.23055.
    PubMed     Text format     Abstract available


  216. MARKT SC, Shui IM, Unger RH, Urun Y, et al
    ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3).
    Prostate. 2015 Aug 13. doi: 10.1002/pros.23035.
    PubMed     Text format     Abstract available


  217. PARK H, Kim Y, Sul JW, Jeong IG, et al
    Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Prostate. 2015 Aug 7. doi: 10.1002/pros.23057.
    PubMed     Text format     Abstract available


  218. BARRY KH, Moore LE, Liao LM, Huang WY, et al
    Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer.
    Prostate. 2015 Aug 7. doi: 10.1002/pros.23053.
    PubMed     Text format     Abstract available


  219. PRENCIPE M, O'Neill A, O'Hurley G, Nguyen LK, et al
    Relationship between serum response factor and androgen receptor in prostate cancer.
    Prostate. 2015 Aug 7. doi: 10.1002/pros.23051.
    PubMed     Text format     Abstract available


  220. WANG Y, Liu G, Tong D, Parmar H, et al
    Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Prostate. 2015;75:1187-96.
    PubMed     Text format     Abstract available


  221. GONTERO P, Marra G, Soria F, Oderda M, et al
    A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
    Prostate. 2015;75:1177-86.
    PubMed     Text format     Abstract available


    July 2015
  222. THOMAS LN, Merrimen J, Bell DG, Rendon R, et al
    Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
    Prostate. 2015 Jul 22. doi: 10.1002/pros.23054.
    PubMed     Text format     Abstract available


  223. QI D, Wu C, Liu F, Gu K, et al
    Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009.
    Prostate. 2015 Jul 17. doi: 10.1002/pros.23046.
    PubMed     Text format     Abstract available


  224. MOREIRA DM, Nickel JC, Andriole GL, Castro-Santamaria R, et al
    Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.
    Prostate. 2015 Jul 17. doi: 10.1002/pros.23041.
    PubMed     Text format     Abstract available


  225. HO CH, Hsu JL, Liu SP, Hsu LC, et al
    Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway.
    Prostate. 2015 Jul 14. doi: 10.1002/pros.23033.
    PubMed     Text format     Abstract available


  226. YU S, Wang M, Ding X, Xia L, et al
    Testicular orphan nuclear receptor 4 is associated with the radio-sensitivity of prostate cancer.
    Prostate. 2015 Jul 14. doi: 10.1002/pros.23044.
    PubMed     Text format     Abstract available


  227. GANDAGLIA G, Schiffmann J, Schlomm T, Fossati N, et al
    Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.
    Prostate. 2015 Jul 14. doi: 10.1002/pros.23040.
    PubMed     Text format     Abstract available


  228. LAWRENCE MG, Pook DW, Wang H, Porter LH, et al
    Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.
    Prostate. 2015 Jul 14. doi: 10.1002/pros.23039.
    PubMed     Text format     Abstract available


  229. SZULKIN R, Whitington T, Eklund M, Aly M, et al
    Prediction of individual genetic risk to prostate cancer using a polygenic score.
    Prostate. 2015 Jul 14. doi: 10.1002/pros.23037.
    PubMed     Text format     Abstract available


  230. KESHARI KR, Wilson DM, Van Criekinge M, Sriram R, et al
    Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.
    Prostate. 2015 Jul 14. doi: 10.1002/pros.23036.
    PubMed     Text format     Abstract available


  231. VALKENBURG KC, Hostetter G, Williams BO
    Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice.
    Prostate. 2015 Jul 2. doi: 10.1002/pros.23032.
    PubMed     Text format     Abstract available


  232. DIKOV D, Bachurska S, Staikov D, Sarafian V, et al
    Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate.
    Prostate. 2015;75:1074-84.
    PubMed     Text format     Abstract available


  233. BERG WT, Danzig MR, Pak JS, Korets R, et al
    Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes.
    Prostate. 2015;75:1085-91.
    PubMed     Text format     Abstract available


  234. DAVALOS RV, Bhonsle S, Neal RE 2nd
    Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy.
    Prostate. 2015;75:1114-8.
    PubMed     Text format     Abstract available


  235. DUBOIS L, Stridsberg M, Kharaziha P, Chioureas D, et al
    Malignant cell-derived extracellular vesicles express different chromogranin epitopes compared to prostasomes.
    Prostate. 2015;75:1063-73.
    PubMed     Text format     Abstract available


    June 2015
  236. FANG X, Gyabaah K, Nickkholgh B, Cline JM, et al
    Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate.
    Prostate. 2015;75:988-1000.
    PubMed     Text format     Abstract available


  237. YANG S, Zhang J, Zhang Y, Wan X, et al
    KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation.
    Prostate. 2015;75:936-46.
    PubMed     Text format     Abstract available


  238. UYGUR B, Abramo K, Leikina E, Vary C, et al
    SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
    Prostate. 2015;75:907-16.
    PubMed     Text format     Abstract available


  239. DAVALIEVA K, Kostovska IM, Kiprijanovska S, Markoska K, et al
    Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
    Prostate. 2015 Jun 12. doi: 10.1002/pros.23034.
    PubMed     Text format     Abstract available


  240. FUJITA Y, Kojima T, Kawakami K, Mizutani K, et al
    miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
    Prostate. 2015 Jun 12. doi: 10.1002/pros.23031.
    PubMed     Text format     Abstract available


  241. SAAR M, Korbel C, Linxweiler J, Jung V, et al
    Orthotopic tumorgrafts in nude mice: A new method to study human prostate cancer.
    Prostate. 2015 Jun 12. doi: 10.1002/pros.23027.
    PubMed     Text format     Abstract available


  242. VEITONMAKI T, Murtola TJ, Maattanen L, Taari K, et al
    Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial.
    Prostate. 2015 Jun 12. doi: 10.1002/pros.23020.
    PubMed     Text format     Abstract available


  243. GRAVINA GL, Mancini A, Muzi P, Ventura L, et al
    CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    Prostate. 2015 Jun 12. doi: 10.1002/pros.23007.
    PubMed     Text format     Abstract available


  244. BERG KD, Roder MA, Thomsen FB, Vainer B, et al
    The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naive advanced prostate cancer treated with primary androgen deprivation therapy.
    Prostate. 2015 Jun 5. doi: 10.1002/pros.23026.
    PubMed     Text format     Abstract available


  245. ANTWI SO, Steck SE, Su LJ, Hebert JR, et al
    Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP).
    Prostate. 2015 Jun 5. doi: 10.1002/pros.23025.
    PubMed     Text format     Abstract available


  246. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
    Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.
    Prostate. 2015 Jun 5. doi: 10.1002/pros.23021.
    PubMed     Text format     Abstract available


  247. PALLER CJ, Kanaan YM, Beyene DA, Naab TJ, et al
    Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status.
    Prostate. 2015 Jun 5. doi: 10.1002/pros.23018.
    PubMed     Text format     Abstract available


    May 2015
  248. YANG M, Wang J, Wang L, Shen C, et al
    Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Prostate. 2015 May 27. doi: 10.1002/pros.23017.
    PubMed     Text format     Abstract available


  249. HUANG Y, Shen P, Chen X, Chen Z, et al
    Transcriptional regulation of BNIP3 by Sp3 in prostate cancer.
    Prostate. 2015 May 27. doi: 10.1002/pros.23029.
    PubMed     Text format     Abstract available


  250. PALLER CJ, Rudek MA, Zhou XC, Wagner WD, et al
    A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
    Prostate. 2015 May 27. doi: 10.1002/pros.23024.
    PubMed     Text format     Abstract available


  251. KANTOR ED, Lipworth L, Fowke JH, Giovannucci EL, et al
    Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study.
    Prostate. 2015 May 27. doi: 10.1002/pros.23019.
    PubMed     Text format     Abstract available


  252. CHEN H, Yu H, Wang J, Zhang Z, et al
    Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.
    Prostate. 2015 May 25. doi: 10.1002/pros.23008.
    PubMed     Text format     Abstract available


  253. LI Q, Li Q, Nuccio J, Liu C, et al
    Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.
    Prostate. 2015 May 19. doi: 10.1002/pros.23011.
    PubMed     Text format     Abstract available


  254. RUBICZ R, Zhao S, April C, Wright JL, et al
    Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
    Prostate. 2015 May 18. doi: 10.1002/pros.23016.
    PubMed     Text format     Abstract available


  255. CONTEDUCA V, Caffo O, Derosa L, Veccia A, et al
    Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
    Prostate. 2015 May 15. doi: 10.1002/pros.23014.
    PubMed     Text format     Abstract available


  256. LISS MA, Xu J, Chen H, Kader AK, et al
    Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
    Prostate. 2015 May 15. doi: 10.1002/pros.23012.
    PubMed     Text format     Abstract available


  257. LIU C, Lou W, Armstrong C, Zhu Y, et al
    Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
    Prostate. 2015 May 13. doi: 10.1002/pros.23015.
    PubMed     Text format     Abstract available


  258. KJAER TN, Ornstrup MJ, Poulsen MM, Jorgensen JO, et al
    Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
    Prostate. 2015 May 4. doi: 10.1002/pros.23006.
    PubMed     Text format     Abstract available


  259. SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
    The prognostic value of reactive stroma on prostate needle biopsy: a population-based study.
    Prostate. 2015;75:662-71.
    PubMed     Text format     Abstract available


  260. ZHANG W, Ren SC, Shi XL, Liu YW, et al
    A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
    Prostate. 2015;75:653-61.
    PubMed     Text format     Abstract available


  261. MOUSAVI S, Panjehpour M, Izadpanahi MH, Aghaei M, et al
    Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues.
    Prostate. 2015;75:735-47.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: